|Bid||231.79 x 800|
|Ask||239.09 x 800|
|Day's range||231.11 - 234.75|
|52-week range||220.86 - 319.76|
|Beta (5Y monthly)||0.08|
|PE ratio (TTM)||23.30|
|Earnings date||13 Feb 2024 - 19 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||323.48|
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
With its stock down 13% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). It is possible that...
For many, the main point of investing is to generate higher returns than the overall market. But every investor is...